Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BRISOTE benralizumab add-on versus step-up high-dose ICS-LABA in uncontrolled eosinophilic asthma
CTR20251810Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of benralizumab in eosinophilic asthma (EA), asthma, sponsored by AstraZeneca. Started Sep 2025; status: terminated.
02
Drugs
benralizumab
03
Conditions
eosinophilic asthma (EA)asthma
Beyond the preview
Go deeper on CTR20251810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251810.